Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Wegovy stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Sep 9, 2026

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 2026·2 sources
00
Sep 7, 2026

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 2026·2 sources
00
Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 2026·1 source
00
May 7, 2026

Novo Nordisk Reports Positive Earnings on Oral Wegovy Development Progress

Novo Nordisk's stock price and earnings received a boost following less-negative news about the development of an oral version of its blockbuster weight loss drug Wegovy, marking progress in the company's efforts to create a pill formulation.

May 7, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

Topics

Clinical trialsDrug Policy, Pricing & ApprovalObesity treatmentNovo NordiskDrug safetyAdolescent healthGLP-1 drugsZepboundChildhood obesityWeight loss drugsEli LillyFoundaoRetatrutideNovo NordiskDrug pricingGLP-1 / Weight-Loss MedicationsCompounding pharmaciesPrescription drug costsWeight loss medications & GLP-1 drugsPharmaceutical earningsPharmaceutical IndustryLifestyle, Wellness and NutritionReal world evidenceDrug Approval and Clinical TrialsGLP-1 medicationsSupplementationEvidence based supplementationWeight managementRespiratory healthPharmaMetabolic healthCorporate earningsBig Tech stock performance

Related entities

World Health OrganizationUnited KingdomUnited StatesHims & HersOzempicDenmarkCopenhagenSemaglutideGeriatric medicineIndiaLiver disease